Who Wants to Live Forever?

Highlander was, at its core, a film about immortality wrapped in sword fights and carried by the unmistakable soundtrack of Queen. “Who wants to live forever?” was not asked as a policy question, nor as an investment thesis, but as a kind of existential provocation. The answer, at the time, seemed obvious: no one, at least not seriously.

And yet, here we are.

Somewhere between geopolitical summits and biotech conferences, the question has quietly migrated into the real world. There are persistent accounts—half anecdote, half strategic curiosity—of discussions between Vladimir Putin and Xi Jinping touching on longevity and the possibility of extending human life well beyond 150 years. Whether these conversations are exaggerated or not is almost secondary. The fact that such a topic can be plausibly attributed to two of the most powerful leaders on earth tells you everything about where the frontier of ambition has moved.

In Europe, the issue presents itself in a more familiar and less glamorous form. The continent is aging, structurally and predictably, its demographic curve bending downward while policymakers compensate through immigration and fiscal engineering (higher taxes to be blunt). Longevity, in the European context, is something to be managed. In the United States, it is increasingly something to be engineered. The Food and Drug Administration still insists that aging is not a disease, which creates a peculiar situation in which scientists are trying to solve a problem that officially does not exist, at least not in regulatory language.

That has not slowed investment. If anything, it has refined it. Jeff Bezos and Yuri Milner have poured billions into Altos Labs, assembling a concentration of scientific talent that resembles less a startup and more a state program without a flag. Peter Thiel, Larry Ellison, and Sam Altman have all, in different ways, aligned themselves with the idea that aging is a technical constraint waiting to be lifted.

The science underpinning this ambition is at once elegant and disconcerting. For decades, aging was understood as damage—cells deteriorating under the weight of time. Now it is increasingly described as a failure of information. The DNA remains intact, but the instructions governing it—epigenetic signals—become scrambled. Cells do not simply break; they lose their ability to remember what they are supposed to do.

The most unsettling confirmation of this comes from the beginning of life itself. When an embryo forms, it inherits age from both parents. The biological material is, in a very literal sense, not young. And yet, within a matter of days, the system resets. The embryo undergoes what is now referred to as natural rejuvenation, stripping away accumulated markers of age and returning to a baseline that can only be described as new. It is a process so fundamental that it went unnoticed for centuries, perhaps because it was hiding in plain sight.

The implication is difficult to ignore: youth is not given, it is reconstructed. If nature can do it once, the question becomes whether it can be done again, deliberately.

This is where modern longevity research situates itself. Shinya Yamanaka demonstrated that cells could be pushed back toward a more youthful state using a specific set of genetic factors. The discovery was profound enough to earn a Nobel Prize, and problematic enough to immediately raise concerns about uncontrolled cell growth and cancer. Turning back time, it turns out, is not a delicate operation.

Researchers such as Juan Carlos Izpisua Belmonte refined the approach, introducing the idea of partial reprogramming—less a full reset and more a calibrated adjustment. In animal models, the results bordered on the improbable: older organisms regaining vitality, tissues recovering function, biological age appearing, at least partially, reversible. It is the kind of outcome that invites both excitement and suspicion, often in equal measure.

Public figures like David Sinclair have helped translate these developments into a broader narrative, sometimes stretching the boundaries between scientific possibility and near-term expectation. The field itself oscillates between caution and ambition, aware that one misstep—particularly in early human trials—could set it back years.

For now, the strategy is pragmatic. Instead of attempting to reverse aging across the entire body, researchers focus on specific systems. The eye, for example, has become a testing ground because it is relatively contained. Early trials targeting conditions like glaucoma aim not to extend life indefinitely but to restore function—to make a damaged system behave as if it were younger. It is a modest goal, which is precisely why it may succeed.

Outside the laboratory, however, modesty is in short supply. The global wellness industry has already monetized the idea of longevity, offering everything from supplements to experimental therapies, often with confidence that far exceeds the available evidence. It is a parallel economy built on the assumption that if science is moving in a certain direction, the market might as well get there first.

The reality is more restrained, though no less significant. Extending healthy human life by even a few years would represent a transformation comparable to the eradication of major diseases. It would reshape healthcare systems, economies, and perhaps even the structure of society. It would also, inevitably, raise questions about access and inequality that make today’s debates look almost quaint.

So when one returns to the original question—who wants to live forever—the answer is no longer rhetorical. It is being explored, funded, regulated, and, in some cases, quietly tested. Not in the dramatic, sword-wielding sense imagined by Highlander, but in laboratories where time is no longer treated as an absolute, but as a variable.

And perhaps the more relevant question now is not whether we can live to 150, as reportedly contemplated in conversations between global leaders, but whether we understand what such a life would actually mean. Because extending time is one thing. Knowing what to do with it is another entirely.